biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
06:14 Menopause brings sudden body-wide changes, not a slow slide, study says✦06:17 Stem cell implants helped 9 Parkinson's patients move better, maker says✦05:42 Siblings born deaf respond to sounds after a newly approved gene therapy✦06:20 US gives up to $41M to test existing drugs for preventing Alzheimer's✦06:18 80-year-old's blood cells become brain stem cells that test under age 20✦05:46 Pill meant to help older dogs live longer is one FDA step from approval✦12:01 A daily pill for male hair loss passed its second big trial, maker says✦05:56 US gynecologists now back hormone therapy as first choice for hot flashes✦06:14 Menopause brings sudden body-wide changes, not a slow slide, study says✦06:17 Stem cell implants helped 9 Parkinson's patients move better, maker says✦05:42 Siblings born deaf respond to sounds after a newly approved gene therapy✦06:20 US gives up to $41M to test existing drugs for preventing Alzheimer's✦06:18 80-year-old's blood cells become brain stem cells that test under age 20✦05:46 Pill meant to help older dogs live longer is one FDA step from approval✦12:01 A daily pill for male hair loss passed its second big trial, maker says✦05:56 US gynecologists now back hormone therapy as first choice for hot flashes
← All story threadsSTORY THREAD

Ocugen's one-time gene therapy for dry macular degeneration.

1 report so far. New developments are added to this thread as they happen.

  1. Sep 1, 2026
    FIRST PATIENT TREATED IN THE BIG FINAL-STAGE TRIALTrial starts · 237 planned

    One-time gene therapy for a leading cause of vision loss starts big trial

    Ocugen has treated the first person in a 237-person trial of a one-time gene therapy for geographic atrophy, a late form of dry macular degeneration, and says it plans to seek US approval in 2028.